Xin Lang Cai Jing·2025-11-03 21:46Core Viewpoint - Spring Medical experienced a significant stock price increase of 14.47% on October 31, with a trading volume of 235 million yuan, indicating strong market interest and potential investor confidence [1] Financing Summary - On October 31, Spring Medical had a financing buy-in amount of 21.99 million yuan, with a net financing purchase of 2.45 million yuan after 19.53 million yuan in financing repayments [1] - The total financing and securities lending balance reached 40.33 million yuan, accounting for 0.48% of the circulating market value, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - There were no securities lent or sold on the same day, with the securities lending balance also at zero, reflecting a lack of short-selling interest [1] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems, with 99.89% of revenue derived from medical device products [2] - As of September 30, the company reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, up 213.21% year-on-year [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan paid out over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund, both of which are new entrants among the top ten circulating shareholders [3]